Compare Recursion Pharmaceuticals Inc (RXRX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Stanley Black & Decker, Inc. trades at $102.24 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 8.7× Recursion Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SWK | |
|---|---|---|
Market Cap | $1.81B | $15.71B |
Sector | Health | — |
52-Week High | $6.79 | $104.00 |
52-Week Low | $2.84 | $62.12 |
Enterprise Value | $1.33B | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Stanley Black & Decker (SWK) trades at $102.64, down 1.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.57 versus $1.21 expected, driven by margin expansion and strong organic growth. The company announced a $1 billion U.S. investment plan to boost manufacturing and innovation, signaling strategic growth commitment.
The outlook is positive with improving profitability and debt reduction, but risks include competitive pressures and economic sensitivity. Analysts are mixed with a $93.67 consensus target below current price, suggesting cautious optimism. Upside hinges on continued execution of cost savings and market share gains in tools and infrastructure sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
